[1]
Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, Furlan A, Gilron I, Gordon A, Morley-Forster PK, Sessle BJ, Squire P, Stinson J, Taenzer P, Velly A, Ware MA, Weinberg EL, Williamson OD, Canadian Pain Society. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain research & management. 2014 Nov-Dec:19(6):328-35
[PubMed PMID: 25479151]
Level 3 (low-level) evidence
[2]
Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA. Pregabalin for neuropathic pain in adults. The Cochrane database of systematic reviews. 2019 Jan 23:1(1):CD007076. doi: 10.1002/14651858.CD007076.pub3. Epub 2019 Jan 23
[PubMed PMID: 30673120]
Level 1 (high-level) evidence
[3]
Bidari A, Moazen-Zadeh E, Ghavidel-Parsa B, Rahmani S, Hosseini S, Hassankhani A. Comparing duloxetine and pregabalin for treatment of pain and depression in women with fibromyalgia: an open-label randomized clinical trial. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences. 2019 Jun:27(1):149-158. doi: 10.1007/s40199-019-00257-4. Epub 2019 Mar 14
[PubMed PMID: 30877484]
Level 1 (high-level) evidence
[4]
Abou-Khalil BW. Update on Antiepileptic Drugs 2019. Continuum (Minneapolis, Minn.). 2019 Apr:25(2):508-536. doi: 10.1212/CON.0000000000000715. Epub
[PubMed PMID: 30921021]
[5]
Goodman CW, Brett AS. A Clinical Overview of Off-label Use of Gabapentinoid Drugs. JAMA internal medicine. 2019 May 1:179(5):695-701. doi: 10.1001/jamainternmed.2019.0086. Epub
[PubMed PMID: 30907944]
Level 3 (low-level) evidence
[6]
Parikh SK, Silberstein SD. Current Status of Antiepileptic Drugs as Preventive Migraine Therapy. Current treatment options in neurology. 2019 Mar 18:21(4):16. doi: 10.1007/s11940-019-0558-1. Epub 2019 Mar 18
[PubMed PMID: 30880369]
[7]
Bendtsen L, Zakrzewska JM, Abbott J, Braschinsky M, Di Stefano G, Donnet A, Eide PK, Leal PRL, Maarbjerg S, May A, Nurmikko T, Obermann M, Jensen TS, Cruccu G. European Academy of Neurology guideline on trigeminal neuralgia. European journal of neurology. 2019 Jun:26(6):831-849. doi: 10.1111/ene.13950. Epub 2019 Apr 8
[PubMed PMID: 30860637]
[8]
Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy research. 2007 Feb:73(2):137-50
[PubMed PMID: 17126531]
[9]
Davari M, Amani B, Amani B, Khanijahani A, Akbarzadeh A, Shabestan R. Pregabalin and gabapentin in neuropathic pain management after spinal cord injury: a systematic review and meta-analysis. The Korean journal of pain. 2020 Jan 1:33(1):3-12. doi: 10.3344/kjp.2020.33.1.3. Epub
[PubMed PMID: 31888312]
Level 1 (high-level) evidence
[10]
Vertigan AE, Kapela SL, Ryan NM, Birring SS, McElduff P, Gibson PG. Pregabalin and Speech Pathology Combination Therapy for Refractory Chronic Cough: A Randomized Controlled Trial. Chest. 2016 Mar:149(3):639-48. doi: 10.1378/chest.15-1271. Epub 2016 Jan 12
[PubMed PMID: 26447687]
Level 1 (high-level) evidence
[11]
Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ (Clinical research ed.). 2011 Mar 11:342():d1199. doi: 10.1136/bmj.d1199. Epub 2011 Mar 11
[PubMed PMID: 21398351]
Level 1 (high-level) evidence
[12]
Atış G, Bilir Kaya B. Pregabalin treatment of three cases with brachioradial pruritus. Dermatologic therapy. 2017 Mar:30(2):. doi: 10.1111/dth.12459. Epub 2017 Feb 6
[PubMed PMID: 28168835]
Level 3 (low-level) evidence
[13]
Allen RP, Chen C, Garcia-Borreguero D, Polo O, DuBrava S, Miceli J, Knapp L, Winkelman JW. Comparison of pregabalin with pramipexole for restless legs syndrome. The New England journal of medicine. 2014 Feb 13:370(7):621-31. doi: 10.1056/NEJMoa1303646. Epub
[PubMed PMID: 24521108]
[14]
Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. International clinical psychopharmacology. 2011 Jul:26(4):213-20. doi: 10.1097/YIC.0b013e32834519bd. Epub
[PubMed PMID: 21368587]
Level 1 (high-level) evidence
[16]
Preuss CV, Kalava A, King KC. Prescription of Controlled Substances: Benefits and Risks. StatPearls. 2024 Jan:():
[PubMed PMID: 30726003]
[17]
. Drugs for chronic insomnia. The Medical letter on drugs and therapeutics. 2018 Dec 17:60(1562):201-205
[PubMed PMID: 30625122]
Level 3 (low-level) evidence
[18]
Chalabianloo F, Schjøtt J. [Pregabalin and its potential for abuse]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. 2009 Jan 29:129(3):186-7. doi: 10.4045/tidsskr.08.0047. Epub
[PubMed PMID: 19180163]
[19]
Ortega-Camarero MA, Avila R, Prados Castaño M, Piñero M, Quiralte J, Cimbollek S. Challenge-based pregabalin induced urticaria and angioedema. A case report. Allergologia et immunopathologia. 2012 Sep-Oct:40(5):323. doi: 10.1016/j.aller.2011.09.012. Epub 2012 Jan 21
[PubMed PMID: 22266144]
Level 3 (low-level) evidence
[20]
Andrade C. Safety of Pregabalin in Pregnancy. The Journal of clinical psychiatry. 2018 Oct 2:79(5):. pii: 18f12568. doi: 10.4088/JCP.18f12568. Epub 2018 Oct 2
[PubMed PMID: 30289631]
[21]
Abrahamsson T, Berge J, Öjehagen A, Håkansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study. Drug and alcohol dependence. 2017 May 1:174():58-64. doi: 10.1016/j.drugalcdep.2017.01.013. Epub 2017 Feb 28
[PubMed PMID: 28315808]
[22]
Evoy KE, Morrison MD, Saklad SR. Abuse and Misuse of Pregabalin and Gabapentin. Drugs. 2017 Mar:77(4):403-426. doi: 10.1007/s40265-017-0700-x. Epub
[PubMed PMID: 28144823]